Parallel Funding, Investors & Competitors

Parallel has raised $190M across 5 funding rounds, most recently a $100M Series D in June 2019.

Last Parallel funding round

$100M

Series D · Jun 2019

Cumulative funding Parallel raised

$190M

across 5 funding rounds

Key investors in Parallel

  • Edward Brown

Parallel Overview

About Parallel

Parallel is a Florida-based cannabis company that cultivates, processes, and distributes medical marijuana products through its network of dispensaries. Operating under the Curaleaf brand, it produces flower, concentrates, edibles, and topicals compliant with state regulations. Parallel serves patients via 25 retail locations across Florida, emphasizing quality control and strain-specific therapies.


Founded

2014

HQ

United StatesAtlanta, GA

Status

Privately held

Customer focus

B2C

Revenue model

Product sales

Parallel Funding History

Parallel has raised a total of $190M across 5 funding rounds.

Parallel's first fundraising round was a $10M Series A in December 2015. The most recent completed round was a $100M Series D in June 2019.

Parallel funding rounds

Parallel funding rounds
DateStageInvestorsRaised
Jun 2019Series DEdward Brown (lead)$100M
Aug 2018Series C-$65M
May 2017Series A-$5M
Dec 2016Series B-$10M
Dec 2015Series A-$10M

Who has invested in Parallel?

1 investor has backed Parallel across its funding rounds, including Edward Brown.

Lead investors include Edward Brown.


Parallel Investors

Investors in Parallel by funding rounds participated
InvestorRoundsRoleFirst check

This data is available for Pro users. Sign up to see all 1 Parallel investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Parallel

Parallel has acquired 3 companies to date.

Last acquisition by Parallel was on April 1st 2021. Parallel acquired Windy City Cannabis for $100M.


Latest Acquisitions by Parallel

Windy City Cannabis
Molecular Infusions
New England Treatment Access
Description
Windy City Cannabis operates four licensed medical cannabis dispensaries among Illinois's 60 total permits. The dispensaries serve communities in Chicago's southwest suburbs through locations in Justice, Lombard, and Romeoville.
Molecular Infusions is a biopharmaceutical company advancing synthetic cannabinoid formulations for pain management and epilepsy. Its liposomal delivery systems improve bioavailability of THC and CBD, with Phase 2 trials underway in Canada.
New England Treatment Access is a Massachusetts-based vertically integrated cannabis company with retail dispensaries in Brookline and Northampton, plus cultivation and processing facilities in Franklin. NETA produces over 250 stock-keeping units including flower, edibles, and concentrates. The company holds multiple licenses in the state's recreational and medical markets.
HQ CountryUnited StatesUnited StatesUnited States
HQ City
Chicago, IL
Nashville, TN
Boston, MA
Deal Date1 Apr 202125 Jun 201914 Jan 2019
Valuation$100Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Parallel acquisitions and their M&A valuation multiples.

Start Free Trial

Parallel Competitors

Parallel competitors include listed companies like Curaleaf, Trulieve Cannabis and Green Thumb Industries, and private ones like Dutchie, Accelerant and PAX Labs.

Public and private companies comparable to Parallel
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
DutchieUnited StatesBend, ORPrivate$45M-$3.8B83.3x
CuraleafUnited StatesUnited StatesPublicly listed$1.3B$238M$2.7B2.7x
AccelerantUnited StatesBaltimore, MDPrivate$913M$282M$2.4B2.6x
Trulieve CannabisUnited StatesUnited StatesPublicly listed$1.2B$314M$2.2B2.4x
PAX LabsUnited StatesSan Francisco, CAPrivate$113M-$1.7B15.0x
Green Thumb IndustriesUnited StatesUnited StatesPublicly listed$1.2B$469M$1.6B1.6x

Parallel Public Comps

Parallel is still privately-owned, but its public comps include Curaleaf, Trulieve Cannabis, Green Thumb Industries, Cronos Group, Glass House Brands, Vireo Growth, Tilray Brands, Verano Holdings, Canopy Growth and SNDL.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Curaleaf$1.3B$238M2.8x2.7x14.9x12.6x
Trulieve Cannabis$1.2B$314M2.1x2.4x7.9x6.7x
Green Thumb Industries$1.2B$469M1.6x1.6x4.0x5.9x
Cronos Group$147M($43M)3.3x2.6x(11.3x)20.3x
Glass House Brands$182M$6M4.9x4.6x162.4x36.6x
Vireo Growth$269M$12M3.7x1.6x81.7x7.4x
Tilray Brands$915M$3M0.8x0.7x218.8x10.7x
Verano Holdings$822M$24M1.0x1.0x36.4x4.0x

This data is available for Pro users. Sign up to see all Parallel competitors and their valuation data.

Start Free Trial

Common questions about Parallel

When was Parallel founded?Parallel was founded in 2014.
Where is Parallel headquartered?Parallel is headquartered in Atlanta, GA, United States.
Is Parallel publicly listed?No, Parallel is a private, VC-backed company.
How much funding has Parallel raised?Parallel has raised $190M across 5 funding rounds.
What was Parallel's last funding round?Parallel's last funding round was a $100M Series D in June 2019, led by Edward Brown.
Who are Parallel's investors?Parallel's investors include Edward Brown.
Which companies are comparable to Parallel?Companies comparable to Parallel include Dutchie, Curaleaf, Accelerant, Trulieve Cannabis, PAX Labs and Green Thumb Industries.
How many companies has Parallel acquired?Parallel has acquired 3 companies, including Windy City Cannabis, Molecular Infusions and New England Treatment Access.
What was the largest acquisition by Parallel?The $100M acquisition of Windy City Cannabis in April 2021 is the largest acquisition Parallel has made to date.

See companies similar to Parallel

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial